Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial aims to evaluate different treatments for patients with acute critical illness who require admission to the intensive care unit. The study will test several medications that are commonly used in intensive care, including different types of blood-thinning medications (enoxaparin, dalteparin, nadroparin, and tinzaparin) given by injection under the skin, as well as human albumin solutions given through a vein.

The study uses a platform design, which means it can evaluate multiple treatments at the same time. Patients will receive one or more of the study medications depending on their specific medical needs. The treatments will be given for up to 90 days while patients are in the intensive care unit.

The study will track various outcomes to determine how well the treatments work, including how long patients survive, how many days they spend without needing life support machines, how many days they spend out of the hospital, and their quality of life after treatment. The study will also monitor patients for any side effects from the medications.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial admission to intensive care

    Your admission to the intensive care unit (ICU) begins after meeting eligibility criteria as an adult patient (18 years or older)

    Medical staff will evaluate your condition to determine which treatment domains are suitable for your situation

  2. Step 2

    Treatment administration

    You may receive one or more of the following medications based on your treatment needs:

    - Injection medications (enoxaparin, dalteparin, nadroparin, or tinzaparin) given under the skin

    - Infusion medications (human albumin solutions) given through an intravenous line

  3. Step 3

    30-day monitoring period

    Medical staff will track your progress for the first 30 days, including:

    - Survival status

    - Days without requiring life support

    - Days spent outside the hospital

    - Presence of confusion or altered mental state (delirium)

  4. Step 4

    90-day follow-up

    Your health status will be evaluated at 90 days, measuring:

    - Survival status

    - Total days without life support

    - Total days spent outside the hospital

  5. Step 5

    180-day assessment

    Final evaluation at 180 days will include:

    - Survival status

    - Quality of life assessment using standardized questionnaires

    - Brief cognitive function test to assess mental abilities

Who can join the trial?

5 criteria

  • Must be 18 years or older
  • Must require urgent admission to the Intensive Care Unit (ICU) - a specialized hospital department that provides continuous monitoring and treatment for critically ill patients
  • Must qualify for at least one active treatment area in the study
  • Both men and women can participate
  • Must be experiencing an acute critical illness - a severe medical condition that requires immediate intensive care treatment

Who cannot join the trial?

9 criteria

  • Age below 18 years old (minors are not eligible)
  • Patients not admitted to an intensive care unit (a specialized hospital department that provides intensive medical care)
  • Patients who are not in a state of acute critical illness (severe, sudden medical condition requiring immediate intensive medical care)
  • Patients who are unable to provide informed consent and do not have a legally authorized representative to provide consent on their behalf
  • Patients who have previously participated in this clinical trial
  • Patients who are currently participating in another interventional clinical trial that could interfere with this study
  • Patients who are pregnant or breastfeeding, unless specifically allowed by individual intervention protocols
  • Patients with known allergies or hypersensitivity to any of the study medications
  • Patients with medical conditions that would make participation unsafe or could interfere with the study results
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tinzaparin

    is a low‑molecular‑weight heparin that is given as a sub‑cutaneous injection. In the trial it is being tested to see how well it helps prevent blood clots in patients who are very sick and in the intensive care unit.

  • Nadroparin

    is another low‑molecular‑weight heparin administered by sub‑cutaneous injection. The study is looking at its ability to stop clot formation in critically ill adults, comparing it with other similar medicines.

  • Enoxaparin

    is a widely used low‑molecular‑weight heparin that is also given by sub‑cutaneous injection. In this trial it is evaluated for its effectiveness in preventing dangerous clots in intensive‑care patients.

  • Dalteparin

    is a low‑molecular‑weight heparin provided as a sub‑cutaneous injection. The trial examines how well it works to reduce the risk of clotting problems in people who are acutely admitted to intensive care.

  • Albumin

    is a solution of human albumin protein that is given through an intravenous (IV) line. In the study it is used to help maintain blood volume and pressure, and to support overall fluid balance in very ill patients.

What is already known about the treatment

  • Tinzaparin

    It is administered by subcutaneous injection, which means it is injected just under the skin. Tinzaparin is an approved low‑molecular‑weight heparin that is widely used in clinical practice. It is mainly prescribed to prevent and treat blood clots such as deep‑vein thrombosis. It works by helping the body’s natural protein antithrombin block a clotting enzyme called factor Xa, and it belongs to the anticoagulant drug class.

  • Nadroparin

    This medication is given as a subcutaneous injection. Nadroparin is an approved low‑molecular‑weight heparin that is commonly used in hospitals worldwide. It is used to prevent and treat venous blood clots, especially in patients at risk after surgery or during hospital stays. It enhances antithrombin’s ability to inhibit factor Xa, acting as an anticoagulant.

  • Enoxaparin

    Enoxaparin is delivered by subcutaneous injection. It is a well‑known, approved low‑molecular‑weight heparin that has been studied extensively in medical literature. The drug is mainly used to prevent and treat clot formation, such as after orthopedic surgery or in acute coronary syndrome. It binds to antithrombin and speeds up the inactivation of factor Xa, classifying it as an anticoagulant.

  • Dalteparin

    Dalteparin is administered through a subcutaneous injection. It is an approved low‑molecular‑weight heparin that is routinely used in many countries. The primary use is to prevent and treat blood clots, especially in patients with kidney disease or those undergoing dialysis. It works by boosting antithrombin’s inhibition of factor Xa, placing it in the anticoagulant drug group.

  • Albumin

    Human albumin solution is given as an intravenous infusion, meaning it is poured directly into a vein. Albumin is an established plasma protein product that is approved and widely used in hospitals. It is mainly used to increase blood volume and correct low protein levels in critically ill patients. It works by raising the oncotic pressure in the blood vessels, and it is classified as a plasma volume expander.

Investigated diseases

  • Critical Illness

    A severe medical condition that causes organ dysfunction and requires intensive care treatment. Critical illness develops when one or more vital organ systems begin to fail, leading to severe physiological instability. The condition often involves respiratory failure, circulatory problems, or other major organ dysfunction. Critical illness can develop suddenly (acute) or as a complication of existing medical conditions. The body's stress response during critical illness can affect multiple organ systems simultaneously. Patients with critical illness require constant monitoring and support of vital functions.

  • Delirium

    A serious disturbance in mental abilities that results in confused thinking and reduced awareness of the environment. Delirium causes changes in attention, awareness, and cognition that typically develop over a short period. People with delirium may experience hallucinations, disorientation, and changes in sleep patterns. The condition can fluctuate throughout the day, with symptoms often worsening during the night. Delirium is especially common in intensive care settings.

  • Cognitive Dysfunction

    A condition characterized by difficulties with memory, learning, concentration, and decision making. It involves problems with various mental abilities including thinking, memory, and reasoning. Cognitive dysfunction can affect daily activities and social interactions. The severity can range from mild to severe, affecting different aspects of mental function. The condition can develop gradually or suddenly, depending on the underlying cause.

Trial detailsLast updated 21 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-516208-41-00Estimated enrolment142 000 patientsSponsorRigshospitalet

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.